T1	Participants 114 161	HIV-infected pregnant women and their newborns.
T2	Participants 386 548	first 28 maternal-infant pairs enrolled in a randomized, intravenous immunoglobulin (IVIG)-controlled trial of HIVIG maternal-infant HIV transmission prophylaxis.
T3	Participants 1225 1271	HIV-infected pregnant women and their newborns
